Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Randomized, Double-blind (for OPC-61815 and Placebo), Placebo- and Moxifloxacin Positive-controlled, 4-Period Crossover Trial to Evaluate the Effect of Single Intravenous Administration of OPC-61815 at 16 and 32 mg on QT/QTc Interval in Healthy Male Subjects.

Trial Profile

A Single-center, Randomized, Double-blind (for OPC-61815 and Placebo), Placebo- and Moxifloxacin Positive-controlled, 4-Period Crossover Trial to Evaluate the Effect of Single Intravenous Administration of OPC-61815 at 16 and 32 mg on QT/QTc Interval in Healthy Male Subjects.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs Tolvaptan (Primary) ; Moxifloxacin
  • Indications Heart failure
  • Focus Adverse reactions
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 21 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 15 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Dec 2018.
    • 15 Aug 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top